Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A monoclonal antibody which is linked with yttrium-90 as the drug ibritumomab tiuxetan

Etymologies

Sorry, no etymologies found.

Examples

  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    Yahoo! News: Business - Opinion

  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    Yahoo! News: Business - Opinion

  • ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

    Business Wire Travel News

  • ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

    The Earth Times Online Newspaper

  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    msnbc.com: Top msnbc.com headlines

  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    Yahoo! News: Business - Opinion

  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    msnbc.com: Top msnbc.com headlines

  • ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

    undefined

  • Data from clinical trials suggest that radio-immunotherapy (RIT) consolidation therapy is an important treatment approach for patients with follicular lympho ma (FL), with striking phase 3 results recently published for 90Y-ibritumomab tiuxetan

    SeekingAlpha.com: Home Page

  • -- (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S.

    BioSpace.com Featured News and Stories

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.